A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy

International Journal of Cancer

Volumn 123, Issue 4, 2008, Pages 942-950

  Sun, Qiming ^a   Xu, Qian ^a   Dong, Xiangbai ^a   Cao, Lin ^a   Huang, Xiaofeng ^a   Hu, Qingang ^a   Hua, Zi Chun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antiangiogenesis; ATF; Extracellular matrix degradation; uPA receptor; VAS

Indexed keywords

ALV PROTEIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MATRIGEL; PLASMIN; PROTEIN; UROKINASE; UROKINASE RECEPTOR; VASOSTATIN; CALRETICULIN; CELL SURFACE RECEPTOR; PEPTIDE FRAGMENT; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CANCER SURVIVAL; CELL ADHESION; CELL ASSAY; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; COLON ADENOCARCINOMA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SURVIVAL TIME; TUMOR CELL; VALIDATION PROCESS; ZYMOGRAPHY; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; COLON TUMOR; CYTOLOGY; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; LUNG TUMOR; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CALRETICULIN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 47049107900     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23537     Document Type: Article

References (43)

1. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-21.
2. Pruneri G, Bertolini F, Soligo D, Carbonib N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-401.
3. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
5. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-7.
6. Choong PF, Nadesapilla AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003;46-58.
7. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006;5:1760-71.
8. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 1992;667:1-12.
9. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
10. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
11. Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cane Res 1991;57:273-28.
12. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning WD, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylate variants. J Biol Chem 1990;265:6453-60.
13. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990;9:467-74.
14. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993;90:5021-5.
15. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Canc Inst 2002;94:597-606.
16. Fabbrini MS, Carpani D, Bello-Rivero I, Soria MR. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. Faseb J 1997;11:1169-76.
17. Mohanam S, Chandrasekar N, Yanamandra N, Khawar S, Mirza F, Dinh DH, Olivero WC, Rao JS. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene 2002;21:7824-30.
18. Takei Y, Mizukami H, Saga Y, Kobayashi H, Suzuki M, Matsushita T, Ozawa K, Suzuki M. Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro. Int J Canc 2005;113:54-58.
19. Bu X, Khankaldyyan V, Gonzales-Gomez I, Groshen S, Ye W, Zhuo S,
20. Pons J, Stratton JR, Rosenberg S, Laug WE. Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest 2004;84:667-78.
21. Mohan PM, Chintala SK, Mohanam S, Gladson CL, Kim ES, Gokaslan ZL, Lakka SS, Roth JA, Fang B, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 1999;59:3369-73.
22. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005;280:36529-40.
23. Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 2006;28:831-9.
24. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-56.
25. Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999;94:2461-68.
26. Yao L, Pike SE, Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 2002;71:47-53.
27. Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, Tosato G. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Canc Immunol Immunother 2002;51:358-66.
28. Li L, Yuan YZ, Lu J, Xia L, Zhu Y, Zhang YP, Qiao MM. Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice. Gut 2006;55:259-65.
29. Wang X, Hou M, Tan L, Sun X, Zhang Y, Li P, Zhu Y. A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis. J Canc Res Clin Oncol 2005;131:129-36.
30. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988;107:1589-98.
31. Sun QM, Chen LL, Cao L, Fang L, Chen C, Hua ZC. An improved strategy for high-level production of human vasostatin 120-180. Biotechnol Prog 2005;21:1048-52.
32. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Canc Res 2004;64:565-71.
33. Lo CM, Buxton DB, Chua GC, Dembo M, Adelstein RS, Wang YL. Nonmuscle myosin IIb is involved in the guidance of fibroblast migration. Mol Biol Cell 2004;15:982-9.
34. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. Faseb J 2000;14:1400-10.
35. Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 1995;50:311-22.
36. Xue L, Greisler HP. Angiogenic effect of fibroblast growth factor-1 and vascular endothelial growth factor and their synergism in a novel in vitro quantitative fibrin-based 3-dimensional angiogenesis system. Surgery 2002;132:259-67.
37. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996;224:344-53.
38. Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, Stoppelli MP, Salvatore M. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cane Res 1997;3:1299-308.
39. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the u. PA:serpin complexes. EMBO J 1997;16:2610-20.
40. Li Y, Knisely JM, Lu W, McCormick LM, Wang J, Henkin J, Schwartz AL, Bu G. Low density lipoprotein (LDL) receptor-related-protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J Biol Chem 2002;277:42366-71.
41. Nassar T, Haj-Yehia A, Akkawi S, Kuo A, Bdeir K, Mazar A, Cines DB, Higazi AA. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem 2002;277:40499-504.
42. Kim KS, Hong YK, Lee Y, Shin JY, Chang SI, Chung SI, Joe YA. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Exp Mol Med 2003;35:578-85.
43. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-43.